CLINICAL AND LABORATORY BASIS FOR THE USE OF EFFERENT THERAPY (ILBI) IN IMPROVING THE FUNCTIONAL STATE OF PERIODONTAL TISSUES IN PATIENTS WITH CHRONIC LEUKEMIA

Authors

  • Orifkhujaeva M.V., Norova M.B. Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan Author

DOI:

https://doi.org/10.5281/zenodo.20184705

Keywords:

chronic leukemia, periodontitis, efferent therapy, intravenous laser blood irradiation (ILBI), VLOK therapy, periodontal tissues, immunomodulation, microcirculation, cytokines, periodontal pathogens.

Abstract

Chronic leukemia is associated with profound immune dysfunction, microcirculatory disorders, thrombocytopenia, and granulocytopenia, which collectively lead to severe, rapidly progressive, and treatment-resistant periodontitis. Efferent therapy methods, particularly intravenous laser blood irradiation (ILBI), have emerged as promising adjunctive modalities for managing periodontal disease in this vulnerable patient population. This literature review analyzes the clinical and laboratory basis for the use of ILBI (VLOK therapy) in improving the functional state of periodontal tissues in patients with chronic leukemia. The key mechanisms of action include immunomodulation (normalization of immunoglobulin levels, reduction of proinflammatory cytokines), improvement of blood rheology and microcirculation, antioxidant effects, antimicrobial activity, and stimulation of reparative processes in periodontal tissues. Clinical studies demonstrate that ILBI significantly reduces gingival bleeding (BOP reduction by 4.8-fold), decreases periodontal pocket depth, increases salivary flow rate (from 0.127 to 0.28 mL/min), normalizes IgG and IgE levels (29.3% increase and 79.9% reduction respectively), suppresses proinflammatory cytokines (4.4–4.7-fold reduction), and reduces periodontopathogen load (63.6% reduction for T. denticola, 57.0% for A. actinomycetemcomitans). The evidence supports the integration of ILBI into comprehensive periodontal treatment protocols for chronic leukemia patients as a safe, pathogenetically justified, and clinically effective efferent therapy modality.

References

1. Al-Azri, A. R., Al-Rawas, A. S., & Al-Kindi, S. S. (2021). Oral manifestations of hematological malignancies: A diagnostic and management challenge. Journal of Cancer Research and Therapeutics, 17(2), 295–302.

2. Botushanov, P. I., & Marinova, M. S. (2019). Microbiological and immunological aspects of periodontitis in patients with chronic leukemia. International Journal of Stomatology & Occlusion Medicine, 12(1), 15–21.

3. Elad, S. (2020). Oral complications in patients with leukemia: pathogenesis and clinical management. Supportive Care in Cancer, 28(3), 1023–1031.

4. Garcia-Lopez, M. (2022). T-cell regulation and persistent inflammation in periodontal tissues of leukemic patients. Clinical Immunology, 238, 109–117.

5. Gomes, A. C., & Silva, B. T. (2022). Efficacy of low-level laser therapy (LLLT) in the treatment of chemotherapy-induced oral mucositis: A systematic review. Lasers in Medical Science, 37(4), 2105–2118.

6. Hallek, M., Shanafelt, T. D., & Eichhorst, B. (2018). Chronic lymphocytic leukemia. Lancet, 391(10129), 1524–1537.

7. Henderson, J. (2024). Antigen presentation defects and adaptive immune delay in periodontal pathogenesis. Mucosal Immunology, 17(2), 201–211.

8. Hong, C. H. (2021). Cytokine profiles and oral inflammation in chronic leukemia. Frontiers in Immunology, 12, 789–796.

9. Hopper, C. (2024). RANKL/OPG imbalance and osteoclast activity in leukemia-associated periodontitis. Bone, 180, 117–125.

10. Kim, H. (2023). Cytotoxic T-cell deficiency and impaired pathogen elimination in chronic leukemia. Journal of Hematology & Oncology, 16(1), 45.

11. Lalla, R. V. (2020). Immunosuppression and oral mucosal barrier dysfunction in hematologic malignancies. Journal of Oral Pathology & Medicine, 49(5), 412–418.

12. Lee, J. H. (2024). IL-1β, TNF-α and IL-6 as biomarkers of periodontal destruction in chronic leukemia. Journal of Periodontal Research, 59(1), 55–64.

13. Martínez, A. (2023). Proinflammatory cytokines and epithelial barrier penetration in periodontal tissues. Periodontology 2000, 91(1), 134–142.

14. Norova, M. B., & Orifkhujaeva, M. V. (2026). Comparative assessment of oral mucosa and periodontal tissues in patients with chronic leukemia. Bulletin of Fundamental and Clinical Medicine, 2(22), 539–543.

15. Peterson, D. E. (2022). Predicting periodontal disease progression in immunocompromised patients: immunological biomarkers. Oral Diseases, 28(4), 1122–1129.

16. Schmalz, G., & Ziebolz, D. (2020). The interface between dentistry and hematology: A clinical update. Clinical Oral Investigations, 24(9), 2957–2969.

17. Schneider, S. (2023). Chemotherapy-induced trophic effects and delayed regeneration of oral mucosa. Oral Oncology, 136, 106–114.

18. Socransky, S. S., & Haffajee, A. D. (2005). Periodontal microbial ecology. Periodontology 2000, 38(1), 135–187.

19. Zhang, W. (2023). Microbiome dysbiosis and virulence factor activation in leukemic patients with periodontitis. Journal of Clinical Periodontology, 50(2), 210–220.

20. Zaynutdinov, S. S., & Rasulova, N. A. (2024). Intravenous laser blood irradiation (ILBI) in the complex treatment of inflammatory oral diseases. Uzbekistan Medical Journal, 65(1), 112–119.

21. Ahmedov, Sh. P. (2022). Disturbance of oral microbiocenosis in patients with leukemia. Integrative Dentistry and Maxillofacial Surgery, 1(1), 105–108.

22. Ismoilova, G. N. (2023). Effectiveness of local antiseptic therapy in oral mucosal diseases. Clinical Medicine, (1), 46–51.

23. Kadyrov, A. A. (1999). Destructive changes of periodontal tissues in chronic leukemia. Dentistry and Medicine, 1(2), 41–45.

24. Khamidova, F. M. (2024). Pathomorphology of oral mucosal inflammation in secondary immunodeficiency. Problems of Biology and Medicine, (5), 251–255.

25. Nazarova, M. B. (2023). Clinical and immunological evaluation of oral health in patients with hemoblastosis (Doctoral dissertation, Bukhara State Medical Institute).

Downloads

Published

2026-05-14